SEATTLE (dpa-AFX) - Exscientia plc (EXAI) said it will be expanding work
with Amazon Web Services to use the cloud provider's artificial intelligence and
machine learning services to power its platform for end-to-end drug discovery
and automation. Exscientia's platform, which is built using AWS technologies,
supports its Design-Make-Test-Learn loops and spans generative AI, active
learning, ML, physics-based systems and many other predictive methods.

'Extending our collaboration with AWS beyond our DesignStudio to include the
robotic automation of synthesis and testing of our molecular designs was the
logical next step for Exscientia,' said John Overington, Chief Technology
Officer of Exscientia.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX